| Date | Title | Description |
| 04.06.2012 | Targacept CEO deBethizy resigns from the N.C. biotech | Targacept in April announced a restructuring that will lay off 65 employees and cut the size of the company nearly in half. The layoffs are set to be completed by June 30. The remaining workers are those focused on clinical stage programs t... |
| 03.05.2012 | Targacept’s drug pipeline must fill gap left by lead drug’s phase 3 failure | Winston-Salem, North Carolina-based Targacept releases first-quarter earnings today after the markets close. The failure of TC-5214 led the company to announce a restructuring that included layoffs of nearly half of its workforce. On Targac... |
| 25.04.2012 | Targacept restructuring plan calls for layoffs of 46 percent of workforce | The restructuring and layoffs don’t come as a surprise. When Targacept’s lead drug failed it final phase 3 study last month, the company signaled that corporate changes were coming. Layoffs are expected to be completed by June 30, Targacept... |
| 11.04.2012 | Asthma compound hits just one of two phase 2 goals, TRGT reanalysis shows | In the asthma study, TC-6987 was evaluated on its ability to increase an asthma patient’s expiratory volume — the amount of air a patient can blow out after full inspiration. The drug candidate could be used in addition to existing low-dose... |
| 27.03.2012 | Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials | TC-6987 was studied in two separate exploratory phase 2 studies, one for asthma and another in diabetes. In the asthma study, the compound was better than a placebo at increasing forced expiratory volume — the amount of air a patient can bl... |
| 20.03.2012 | Targacept, AZN drop depression candidate after third phase 3 failure | Targacept had planned five phase 3 studies for TC-5214, its lead drug candidate; two trials were to study fixed dosing and another two trials to study flexible dosing. The psychiatric community is undecided whether flexible or fixed dosing ... |
| 21.02.2012 | Depression remains TRGT’s lead target, but CEO touts other shots on goal | “While many eyes externally have been focused only on 5214 and the Renaissance studies, we have a deep clinical pipeline of five mid- to late-stage product candidates that represent multiple different innovative (neuronal nicotinic receptor... |
| 07.02.2012 | Tale of 2 pharmas: GSK’s pipeline shows promise, AZN’s prospects dim | Since AstraZeneca’s first restructuring in 2007, the company has cut more than 21,000 jobs. With the latest restructuring AstraZeneca is closing two neuroscience R&D sites, one in Sweden and another in Canada. A total of 2,200 R&D p... |
| 05.01.2012 | AstraZeneca takes on TRGT’s Alzheimer’s disease drug candidate | The Targacept/AstraZeneca collaboration includes another experimental Alzheimer’s disease treatment: AZD3480. The companies have studied the compound in six phase 2 studies covering a range of cognitive disorders that include attention-defi... |
| 09.12.2011 | CeNeRx, expecting trial results and drug partner in 2012, raises $4.8M | The Cary, North Carolina company has closed on a fundraise of $4.8 million that the company will apply to its portfolio of central nervous system drug candidates, chiefly TriRima, which is set to complete phase 2b trials early next year. Ex... |
| 05.12.2011 | Targacept pins hopes on second set of phase 2 trials for schizophrenia, ADHD drug | A spinout from tobacco company R.J. Reynolds, Targacept focuses on compounds that target neuronal nicotinic receptors to treat central nervous system disorders. Targacept needs a win. The company last month disclosed that TC-5214, a compoun... |
| 08.11.2011 | TRGT, AZN depression drug’s future rides on three more phase 3 trials | Investors took to the news poorly and Targacept shares plunged by more than 57 percent in trading this morning. But Winston-Salem, North Carolina-based Targacept remains committed to studying TC-5214 and deBethizy reiterated targets to rele... |
| 04.08.2011 | Targacept confident in ADHD compound, plans new trials by 2012 | DeBethizy said drug partner AstraZeneca did due diligence on the compound and the pharma giant even liked it. But for internal reasons, AstraZeneca decided not to license it, deBethizy told analysts during a conference call to discuss secon... |
| 10.06.2011 | Targacept nets $10M more for clinical trials on cognitive disorders candidate | Targacept’s stock offering followed a shelf registration statement last December in which the company gave itself the option to raise up to $150 million to develop its drug candidates. Targacept said most of the proceeds from the May offeri... |
| 20.05.2011 | N.C. biopharma company Targacept prices $75M stock offering | Targacept is directing much of the stock offering proceeds to TC-5619, a compound that drug partner AstraZeneca (NYSE:AZN) evaluated but declined to license. TC-5619 has showed positive results in mid-stage clinical trials studying cognitiv... |
| 17.05.2011 | Targacept’s $75M stock offering targets cognitive disorders R&D | Targacept hoped that drug partner AstraZeneca would be financing the clinical development of the compound. Under a 2005 partnership agreement, AstraZeneca had the option to license the compound and pick up the R&D from Targacept. Had As... |
| 29.03.2011 | North Carolina pharma R&D funding: A snapshot of 2010 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 24.03.2011 | Targacept ADHD drug fails in study; still shows promise for schizophrenia | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 03.03.2011 | Targacept ends GSK alliance due to ‘strategic changes’ in neurosciences | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 08.02.2011 | North Carolinian companies look hard for government incentives | “Innovation” was an oft-mentioned buzzword at the annual Emerging Issues Forum, an event sponsored by North Carolina State University that this year focuses on healthcare.
Underlying the discussion about health practices and new drugs is th... |
| 07.02.2011 | North Carolina biotechs seek incentives but state has no money to give | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| - | AstraZeneca takes on TRGT’s Alzheimer’s disease drug candidate | Targacept (NASDAQ:TRGT) has seen two phase 3 clinical trial failures in the last two months for its depression drug candidate. Now the company has some better news, albeit for a different indication. Drug partner AstraZeneca (NYSE:AZN) will... |
| - | Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials | A Targacept (NASDAQ:TRGT) compound developed for potential applications in asthma and type 2 diabetes has mixed mid-stage clinical trial results that show success in asthma but failure in diabetes.
As a result, Targacept will no longer purs... |
| - | North Carolina biotechs seek incentives but state has no money to give | “Innovation” is one of the most talked about buzz words humming at the annual Emerging Issues Forum, an event sponsored by North Carolina State University that this year focuses on healthcare. The forum run through Tuesday in Raleigh, North... |
| - | CeNeRx, expecting trial results and drug partner in 2012, raises $4.8M | Central nervous system drug development company CeNeRx BioPharma is developing an antidepressant whose novel mechanism causes fewer side effects, and the company is now in active talks with large pharmaceutical companies who could take the ... |
| - | Targacept nets $10M more for clinical trials on cognitive disorders candidate | Targacept (NASDAQ:TRGT) has $10 million in additional funds to apply toward clinical trials on a drug candidate intended for patients with schizophrenia.
The Winston-Salem, North Carolina biopharmaceutical company last month completed a sto... |
| - | Targacept CEO deBethizy resigns from the N.C. biotech | Targacept (NASDAQ:TRGT), already in the midst of a corporate restructuring, must now also search for a new CEO.
Don deBethizy is resigning from his positions as CEO and chairman of the drug development company. In a statement, deBethizy sai... |
| - | Targacept restructuring plan calls for layoffs of 46 percent of workforce | Targacept (NASDAQ:TRGT) is slashing its workforce by nearly half, part of a restructuring plan that comes one month after its lead drug candidate, a depression drug, failed the last of a series of phase 3 clinical trials.
The company is lay... |
| - | Targacept confident in ADHD compound, plans new trials by 2012 | AstraZeneca‘s (NYSE:AZN) decision earlier this year to not license Targacept‘s (NASDAQ:TRGT) compound for attention-deficit/hyperactivity disorder was seen by some as a no confidence vote in the molecule.
But Don deBethizy, CEO of Winston-S... |
| - | Tale of 2 pharmas: GSK’s pipeline shows promise, AZN’s prospects dim | GlaxoSmithKline (NYSE:GSK) released fourth-quarter 2011 and full-year financial results Tuesday, which happens to be Charles Dickens’ birthday. Somehow I think it’s fitting that Britain’s largest pharmaceutical company discussed its finance... |
| - | Targacept’s $75M stock offering targets cognitive disorders R&D | Now that AstraZeneca (NYSE:AZN) has determined it won’t license Targacept‘s compound for schizophrenia, the drug development company is preparing to raise up to $75 million to develop the drug candidate on its own.
Winston-Salem, North Caro... |
| - | Targacept pins hopes on second set of phase 2 trials for schizophrenia, ADHD drug | Drug development company Targacept (NASDAQ:TRGT) has started two mid-stage clinical trials on a compound that could have applications in schizophrenia as well as attention deficit-hyperactivity disorder.
It’s the second round of phase 2 tri... |
| - | Targacept, AZN drop depression candidate after third phase 3 failure | Targacept (NASDAQ:TRGT) and AstraZeneca (NYSE:AZN) are dropping plans to seek regulatory approval on their depression drug candidate after the compound failed its remaining phase 3 clinical trials.
The two drug companies were developing TC-... |
| - | North Carolina pharma R&D funding: A snapshot of 2010 | Research and development spending dollars reached a record $67.4 billion in 2010, a $1.5 billion increase compared with 2009.
North Carolina’s life science companies are certainly part of that mix. A look at the annual reports from public c... |
| - | Targacept’s drug pipeline must fill gap left by lead drug’s phase 3 failure | Targacept‘s (NASDAQ:TRGT) first quarter dealt the company several blows with a phase 3 clinical trial failure for its lead drug candidate and a missed target in another clinical program.
Failure of depression candidate TC-5214 led to the fo... |
| - | N.C. biopharma company Targacept prices $75M stock offering | Biopharmaceutical company Targacept (NASDAQ:TRGT) expects its stock offering will net $70.2 million that will fund development of a compound with targeted applications in schizophrenia and Alzheimer’s disease.
Winston-Salem, North Carolina-... |
| - | Targacept ends GSK alliance due to ‘strategic changes’ in neurosciences | GlaxoSmithKline’s decision to withdraw from some areas of neuroscience research is claiming another North Carolina casualty: Biopharmaceutical company Targacept will terminate its partnership with the pharma giant.
Winston Salem, North Caro... |
| - | TRGT, AZN depression drug’s future rides on three more phase 3 trials | Targacept (NASDAQ:TRGT) remains committed to moving forward with three more phase 3 clinical trials attempting to develop depression’s first new treatment mechanism in decades despite results of one trial showing that the compound partnered... |
| - | Depression remains TRGT’s lead target, but CEO touts other shots on goal | Depression treatment TC-5214 remains Targacept‘s (NASDAQ:TRGT) lead drug candidate and perhaps it was with that in mind that CEO Don DeBethizy started the earnings conference call with an update on that drug program.
But there was nothing n... |
| - | Targacept ADHD drug fails in study; still shows promise for schizophrenia | An experimental attention deficit-hyperactivity disorder (ADHD) drug being developed by Targacept in partnership with AstraZeneca (NYSE:AZN) has failed to hit targets set for a mid-stage clinical trial.
Winston-Salem, North Carolina-based T... |
| - | Asthma compound hits just one of two phase 2 goals, TRGT reanalysis shows | The asthma treatment Targacept (NASDAQ:TRGT) is developing actually did not perform as well in clinical trials as initially thought.
Targacept last month released top-line phase 2 results for TC-6987 that showed the asthma compound met both... |